Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2026

The Nomination Committee for Vitrolife AB (publ) has been established in preparation for the Annual General Meeting (AGM) scheduled for May 6, 2026, in Gothenburg, Sweden. This committee is formed in accordance with the Nomination Committee Charter adopted during the AGM of 2025.

The committee comprises four members, including the Chair of the Board, Jón Sigurdsson. The other members are Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; and Patricia Hedelius, appointed by AMF Fonder & Pension. This diverse team will be responsible for proposing nominations for Board members and auditors, ensuring adherence to the company's governance protocols as they prepare for the upcoming AGM.

Shareholders interested in contributing proposals for the Nomination Committee's consideration are encouraged to reach out directly to the Chair of the Board via email at investors@vitrolife.com. This opens the door for shareholder engagement and allows for a transparent nomination process, reflecting the company's commitment to involving its investor base in important governance matters.

As Vitrolife AB approaches this significant annual event, the establishment of the Nomination Committee highlights its dedication to maintaining robust corporate governance and responsive stakeholder communication. The AGM will serve as a platform for shareholders to discuss the company's future strategies and leadership, and the Nomination Committee will play a pivotal role in shaping that dialogue.

This update was issued on October 29, 2025, reinforcing the company's proactive stance in ensuring that all elements are in place ahead of the meeting. For further inquiries, Amelie Wilson, Investor Relations, can be contacted at awilson@vitrolife.com.

As we approach the Annual General Meeting (AGM) of Vitrolife AB (publ) set for May 6, 2026, the formation of the Nomination Committee provides insightful clues about the company's governance and strategic direction. The committee, composed of members appointed by prominent stakeholders—William Demant Invest, Bure Equity AB, and AMF Fonder & Pension—reflects a diverse ownership base, indicating a concerted effort to balance various interests in corporate governance.

Niels Jacobsen, Patrik Tigerschiöld, and Patricia Hedelius bring a wealth of experience and perspective stemming from their respective roles in investment and pension management. Their involvement suggests a strategic inclination towards robust performance and sustainable growth, both vital for driving shareholder value. The presence of Jón Sigurdsson as the Chairman of the Board reinforces continuity in leadership while ensuring that the company’s vision aligns with stakeholder expectations.

For investors, this is an opportune moment to engage. Shareholders are encouraged to submit proposals to the Nomination Committee, potentially influencing future board appointments and decisions that could affect corporate strategies. This open line of communication indicates a willingness by Vitrolife’s leadership to incorporate shareholder feedback into its governance framework.

From a market perspective, Vitrolife's sophisticated approach to governance must be recognized as favorable. Companies that exhibit strong governance structures often translate that strength into operational success and market resilience. As Vitrolife continues to evolve within the fertility treatments market—an area poised for growth as global awareness and demand increase—stakeholders should monitor the outcomes of the AGM and any shifts in the board that may accompany it.

In conclusion, the upcoming AGM represents both a pivotal meeting for Vitrolife and an opportunity for shareholders to align their investment strategies with the company's governance initiatives, ultimately fostering a more engaged and effective investment community.